Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
  • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07F7/1804—Compounds having Si-O-C linkages

Definitions

• the present invention relates to the field of organic chemistry and more specifically to that of therapeutic chemistry.
• R is an acyl or aralkyl radical, derived from a nitrogenous mono- or bicyclic heterocycle and the hydroxymethyl group in position 2 is in the cis position relative to the plane determined by positions 2 and 5.
• X represents hydrogen, a halogen atom, a nitro group, a lower alkoxy or a trifluoromethyl radical and n is an integer varying from 1 to 3
• is an alkyl radical having from 1 to 10 carbon atoms X and n are defined as above
• carbonyl radical in which the carbonyl radical can be in position 2, 3 or 4
• X represents hydrogen, a halogen, a trifluoromethyl radical, a lower alkoxy or a nitro group and n 'represents an integer varying from 1 to 6.
• Rj and X are defined as above and n 'is an integer varying from 1 to 6
• , X and n ' are defined as above the acyl radical is in position 2, 3 or 4 and A is a mineral or organic anion
• the compounds of formula I can be split into their optical isomers. This gives the (+) isomer and the (-) isomer.
• Retroviral infections are the cause of serious illnesses, especially acquired immunodeficiency syndrome (AIDS) which is an often fatal viral condition, and to a lesser extent hepatitis.
• AIDS acquired immunodeficiency syndrome
• Several compounds of the nucleoside or hetero-nucleoside type are currently used clinically for the treatment of these retroviral conditions. These are the AZT derivatives (3'-azido-2 ', 3'-didesoxythymidine) (Proc. Natl. Acad. Sci. 82, 7096-7100, 1985), ddC (2', 3'-didesoxycytidine) ( Proc. Natl. Acad. Sci.
• the compounds of the invention have the property of inhibiting the replication of human retroviruses, in particular HIV and the hepatitis B virus (HBV).
• HBV hepatitis B virus
• These compounds include in their structure a 1,4-dihydro-1-methyl-3-quinoleylcarbonyl entity attached to the exocyclic amino group of cytidine. This particular structural entity confers in pharmacology experimental the property of increasing and facilitating the passage of the blood-brain barrier (Pharmacol. Ther. 19, 337-396, 1983 - Methods Enzymol. 112, 381-396, 1985 - Drug. Des. Del, 51-64 , (1986) - J. Med. Chem. 31, 244-249, 1988 - J. Med. Chem. 32, 1782-1788, 1989 - J. Med. Chem. 32, 1774-1781, 1989).
• the invention also relates to the process for obtaining the compounds of general formula I which consists in subjecting a 5- (cytosinyl-1) 1, 3-oxathiolane çjs to the action of a functional derivative of carboxylic acid of formula ROH where R is an acyl radical derived from an aromatic or dihydroaromatic heterocycle, mono- or bicyclic nitrogen or by the action of an active aralkyl derivative of formula R'Z where R 'is an aralkyl radical derived from an aromatic heterocycle or dihydroaromatic, mono- or bicyclic, nitrogen and Z is an easily cleavable labile radical.
• the functional derivative of ROH acid is a halide, an anhydride, a mixed anhydride formed with a carbodiimide or a reactive ester such as a phenol ester.
• Z is a halogen atom or an alkyl or aryl sulfonyl radical.
• a subject of the invention is also pharmaceutical compositions with antiviral action, characterized in that they contain, as active principle, at least one compound of general formula I or one of its addition salts with a mineral or organic acid, in combination or as a mixture with an inert, non-toxic, pharmaceutically compatible excipient or vehicle, in particular for topical or general use.
• the content of active ingredient of general form I ranges from 0.1 mg to 100 mg per unit dose depending on the route of administration.
• Cis 2- isomers (diphenylterbutylsilyloxymethyl) -5- [N 4 (3 "-pyridinyl carbonyl) cytosine-1 '-yl] -1, 3-oxathiolane 3
• Cis 2- isomers (terbutyl-diphenyl-silyloxymethyl) -5- (cytosine-1'-yl) -1, 3-oxathiolane 5
• EXAMPLE VIII Isis of Cis 2-hydroxymethyl 5- [N 4 -3 "-quinolinylcarbonyl) cytosin-1'-yl] 1, 3-oxathiolane 8
• 74.4 mg (0.43 mmol) of 3-quinoline carboxylic acid are added, then 96 mg (0.47 mmol) of 1, 3-dicyclohexyl carbodiimide and 63.4 mg (0, 47 mmol) of hydroxybenzotriazole hydrate.
• the mixture is stirred for 1 h at room temperature under nitrogen.
• a white precipitate of dicyclohexylurea appears and 100 mg (0.43 mmol) of 2,3'-dideoxy 3'-thiacytidine are then added.
• a solution of compound 8 (78 mg or 0.20 mmol) is prepared in 4 ml of acetonitrile. 112 ⁇ l (1.8 mmol) of methyl iodide are added and the mixture is heated at 40 ° C. under nitrogen for 24 h. The solvent is removed and the crude residue is then dissolved in the minimum of acetonitrile. It is reprecipitated by addition of ether.
• Cis isomers 2-hydroxymethyl 5- [N 4 - (1 "-methyl 1", 4 "-dihydro 3" - quinolinylcarbonyl) cytosin-1'-yl] -1, 3-oxathiolane 0
• Cis isomers of 2-hydroxymethyl-5- [N 4 - (2- (a, a, a-trifluoro-m-toluidino) nicotinyl) -cytosine-ryl] -1, 3-oxathiolane 11
• the ultracent ⁇ fugeuse used is of the Beckman TL 100 type.
• the counting of radioactive particles was carried out on a Hewlett Packard Tri-Carb Model 1600 device.
• the syncitia are observed with an inverted Labovert microscope.
• the evaluation of the antiviral effect is based on the study of the cytopathogenic effect of the HIV-1 virus on the MT4 cell line.
• the MT4 line originates from T cells isolated from a patient, transformed by the VTLH-1 virus.
• the cytopathogenic effect of the HIV-1 virus results in the formation of giant multinucleated cells called
• MT4 cells are maintained at 3.10 5 cells / ml in RPMI 1640 medium: 10% fetal calf serum decomplemented for 30 min at 56 ° C (hormones, serum growth factors ...), 1% glutamine, 1% penicillin, streptomycin and
• antiviral treatment is permanent. Indeed, it is present before, during and after the viral infection. Successive dilutions are made in 10% fetal calf serum, in order to be able to cultivate MT4 for 8 days and observe the formation of syncitia.
• the MT4 After infection: after an incubation of 1 h at 37 ° C, the MT4 are washed 3 times with RPMI 1640 and cultured at the rate of 3.10 ⁇ cells per milliliter of each of the concentrations of the test compounds in 24-hour plates well. During the passage made on day D3, the MT4 cells are diluted 1/3. The concentration of the antiviral is maintained. Each day, the appearance of syncitia is observed under the microscope in order to detect a possible delay compared to the HIV-1 control. At JQ, the assay of the reverse transcriptase is carried out. If the cells are not infected, then there is protection by the antiviral tested.
• Reverse transcriptase is a DNA RNA dependent polymerase. This enzyme allows replication of retroviruses. Thanks to this, the RNA of the virus, copied into DNA, integrates into the cell genome. Proviral DNA is transcribed by the cell's enzymes into viral RNA.
• 1 ml of culture supernatant is concentrated 100 times by ultracentrifugation for 5 min at 95,000 rpm; the viral pellet obtained after ultracentrifugation is resuspended in 10 ⁇ l of 0.1% NTE + TRITON buffer (polyoxyethylene ether); it is used to lyse the virus and to release reverse transcriptase. In vitro, it is the reverse transcriptase activity which is highlighted.
• This enzyme uses a synthetic poly A matrix having an oligo dT primer having 12 to 18 residues.
• the radioactive substrate for this reaction is [3H] dTTP (radioactive thymidine triphosphate at 1mCi / ml); the newly formed tritiated macromolecules are precipitated with trichloroacetic acid and separated from the free [ 3 H] TTP by filtration.
• the enzymatic activity of reverse transcriptase is measured by the radioactivity incorporated in the poly-rA / poly-dT complexes. This radioactivity is determined in a particle counter, after addition of the scintillating liquid acting as an amplifier.
• the culture material for testing the anti-HBV activity of compounds in vitro consists of duck hepatocytes, infected with duck hepatitis B virus (DHBV), (Antimicrob. Agents Chemother. 1989, 33 , 336-339; J. Med. Virology, 40, 59-64; Antivir. Res. 1993, 21, 155-171; Antimicrob. Agents Chemother.
• the duck hepatitis B virus is recognized as being very close to the human hepatitis B virus (Viral Hepatitis and Liver Disease, 1988, 526-529; Antiviral Research, 1987, 8, 189-199) .
• the culture of duck hepatocytes allows complete replication of DHBV.
• the antiviral activity of the compounds tested is measured as a function of the quantity of viral DNA produced during 10 days of culture of the infected hepatocytes.
• a 3-week-old duckling, reached by DHBV, is used for the preparation of hepatocytes.
• the duck is killed under anesthesia and the isolation of the hepatocytes is carried out according to the methodology of Guillouzou (Research in isolated and cultured hepatocytes, J. Libbey Eurotex Ltd / INSERM, 1986).
• the cells are suspended in Leibowitz medium and 5 ⁇ g / ml of bovine insulin, 7.10 " ⁇ mole of hydrocortisone hemisuccinate and 1.5% of DMSO are added.
• the cell density is 8.10 ⁇ cells, spread out in 100 ⁇ 20 mm culture dishes.
• the test compounds are added to the culture after the cells have been spread.
• the medium is changed daily for 10 days.
• hepatitis B virus viral DNA from duck in the cell supernatant is estimated by the "Dot Blot" hybridization method, according to Fourel et al. (Viral Hepatitis and Liver Disease, 1988, 506-509; Hepatology, 1989, 10, 186-191). inhibition is expressed as a percentage of the amount of DNA present in the cell supernatant, compared to a culture infected with DHBV not treated with a nucleoside derivative.
• DNA deoxyribonucleic acid
• APTS para-toluene sulfonic acid
• RNA ribonucleic acid
• AZT 3'-azido-2'-3'-dideoxy-thymidine or Zidovudine
• DHBV Duck hepatitis B Virus FAB + : "Fast positiv Atomic Bombardment"
• ⁇ HdTTP Thymidine radioactive triphosphate at 1 mCi / ml
• TBDPSCI tetrabutyldiphenylsilyl chloride 3-TC: (-) - (2R, 3S) -2-hydroxymethyl-5- (cytosine-1'-yl) -1, 3-oxathiolane or Lamivudine
• TCIU infectious units
• TsCI tosyle chloride UV: ultra-violet
• HIV Human immunodeficiency virus
• HBV Hepatitis B virus
• VTLH Human lymphotropic T cell virus Table I

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Immunology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9463449

Family Applications (1)

Country Status (19)

Families Citing this family (13)

Citations (2)

Family Cites Families (4)

• 1994
  • 1994-05-24 FR FR9406262A patent/FR2720397B1/fr not_active Expired - Fee Related
• 1995
  • 1995-05-24 BR BR9506244A patent/BR9506244A/pt active Search and Examination
  • 1995-05-24 EP EP95920986A patent/EP0733053A1/fr not_active Withdrawn
  • 1995-05-24 PL PL95312693A patent/PL181713B1/pl unknown
  • 1995-05-24 CN CN95190647A patent/CN1080264C/zh not_active Expired - Fee Related
  • 1995-05-24 JP JP7530108A patent/JPH09502453A/ja not_active Ceased
  • 1995-05-24 CA CA002167930A patent/CA2167930A1/fr not_active Abandoned
  • 1995-05-24 AU AU26209/95A patent/AU688052B2/en not_active Ceased
  • 1995-05-24 FI FI960316A patent/FI960316A7/fi unknown
  • 1995-05-24 RU RU96105063A patent/RU2142462C1/ru active
  • 1995-05-24 HU HU9600155A patent/HU219299B/hu not_active IP Right Cessation
  • 1995-05-24 WO PCT/FR1995/000683 patent/WO1995032200A1/fr not_active Ceased
  • 1995-05-24 CZ CZ96219A patent/CZ21996A3/cs unknown
  • 1995-05-24 KR KR1019960700446A patent/KR100242891B1/ko not_active Expired - Fee Related
  • 1995-05-24 US US08/586,892 patent/US5708000A/en not_active Expired - Fee Related
  • 1995-05-25 NZ NZ287478A patent/NZ287478A/en unknown
• 1996
  • 1996-01-23 NO NO960272A patent/NO306299B1/no not_active IP Right Cessation
  • 1996-01-23 AP APAP/P/1996/000784A patent/AP612A/en active
  • 1996-01-24 OA OA60770A patent/OA10258A/fr unknown

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events